Aimmune Therapeutics presented results from a Phase 2 study evaluating their developmental product for the treatment of peanut allergy, AR101, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 in Barcelona, Spain.
Aimmune is working towards a food allergy treatment system that is taken orally to desensitize the patient. The company’s product in current development targets peanut allergies, but they believe the treatment can be scaled to other food allergens as well.
The results of the Phase 2 efficacy study were presented to the attendees of the EAACI Congress 2015 during the Food Allergy and Omics session on June 7.
AR101 for peanut allergies is on track towards going to market
The Phase 2 clinical study of the immunotherapy treatment works through desensitization, but is taken orally rather than injected or as a patch. It’s made with a combination of naturally-occurring proteins and pharmaceutical-grade ingredients and works as a controlled up-dosing protocol for building desensitization to the allergen.
Aimmune Therapeutics began in 2011 as Allergen Research Corporation to develop treatments for peanut and other food allergies. This is their first product to meet trials towards approval and use. Aimmune plans to take AR101 into its next set of trials later this year.